Protocol Ledger

NCT07548177 · Phase II · RECRUITING

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

Interventional Phase II clinical trial protocol NCT07548177 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-02 Enrollment: 33 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07548177
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)33 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07548177
Protocol FieldVerified Registry Value
NCT IdentifierNCT07548177
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment33 participants (ESTIMATED)
Registered Start Date2026-04-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI